SCHEMBL20889

SCHEMBL20889

N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)COC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.36
USP2 O75604 1/20 0.33
SLCO1B1 Q9Y6L6 1/20 0.33
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9807659 1.00 PAX8 (0.36) PAX8USP2SLCO1B1ALDH1A1
SCHEMBL16429714 0.84 PAX8 (0.35) PAX8
SCHEMBL9617279 0.84 PAX8 (0.38) PAX8USP2ALDH1A1
SCHEMBL1182041 0.84 PAX8 (0.38) PAX8USP2ALDH1A1
SCHEMBL2223107 0.84 PAX8 (0.38) PAX8USP2ALDH1A1
SCHEMBL17748583 0.83 PAX8 (0.36) PAX8USP2SLCO1B1
SCHEMBL1788967 0.82 PAX8 (0.41) PAX8
SCHEMBL5355000 0.82 PAX8 (0.37) PAX8USP2SLCO1B1
SCHEMBL17748555 0.82 PAX8 (0.34) PAX8
SCHEMBL17767378 0.82 PAX8 (0.41) PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10857176-B2 Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan Oligo Médic Inc. (CA) 2020-12-08 US claimed
US-20190247421-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN OLIGO MEDIC INC. 2019-08-15 US claimed
CN-103189435-B Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC. (CA) 2016-02-17 CN claimed
EP-2609149-B1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC (CA) 2015-08-12 EP claimed
US-8784850-B2 Highly biocompatible dual thermogelling chitosan/glucosamine salt composition OLIGO MEDIC INC (CA) 2014-07-22 US claimed
US-20130266549-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITION OLIGO MEDIC INC (CA) 2013-10-10 US claimed
US-8506972-B2 Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC (CA) 2013-08-13 US claimed
EP-2609149-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS Oligo Medic Inc. (CA) 2013-07-03 EP claimed
CN-103189435-A Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions OLIGO MEDIC INC 2013-07-03 CN claimed
US-20120052012-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC. (CA) 2012-03-01 US claimed
WO-2012024785-A1 HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITIONS OLIGO MEDIC INC. (CA) 2012-03-01 WO claimed
EP-0236771-B1 AMINO SUGAR CARBONATING AGENTS AND THEIR PREPARATION SOCIETE DES PRODUITS NESTLE S.A. (CH) 1991-05-08 EP claimed
US-4766209-A REACTING BICARBONATE IONS WITH EITHER GALACTOSAMINE OR GLUCOSAMINE NESTEC S. A. (CH) 1988-08-23 US claimed
EP-0236771-A2 Amino sugar carbonating agents and their preparation SOCIETE DES PRODUITS NESTLE S.A. (CH) 1987-09-16 EP claimed
US-10857176-B2 Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan Oligo Médic Inc. (CA) 2020-12-08 US disclosed
US-20190247421-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN OLIGO MEDIC INC. 2019-08-15 US disclosed
US-20170216341-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN OLIGO MÉDIC INC (CA) 2017-08-03 US disclosed
US-4766209-A REACTING BICARBONATE IONS WITH EITHER GALACTOSAMINE OR GLUCOSAMINE NESTEC S. A. (CH) 1988-08-23 US disclosed
EP-0236771-A2 Amino sugar carbonating agents and their preparation SOCIETE DES PRODUITS NESTLE S.A. (CH) 1987-09-16 EP disclosed
EP-0236771-A2 Amino sugar carbonating agents and their preparation SOCIETE DES PRODUITS NESTLE S.A. (CH) 1987-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10857176-B2 Composition comprising polyglucosamine-glyoxylate solutions mixed with hyaluronan CD44, IDUA, FUT6 PAX8 3547/4885USP2 628/4885SLCO1B1 1828/4885
US-20170216341-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN CD44, IDUA, FUT6 PAX8 3547/4885USP2 628/4885SLCO1B1 1828/4885
US-20190247421-A1 COMPOSITION COMPRISING POLYGLUCOSAMINE-GLYOXYLATE SOLUTIONS MIXED WITH HYALURONAN CD44, IDUA, FUT6 PAX8 3547/4885USP2 628/4885SLCO1B1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.